University of Alabama at Birmingham

Birmingham, Alabama, United States

147 recruiting

Showing 120 of 335 trials

Recruiting
Phase 3

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Coronary Artery Disease ProgressionPremature AtherosclerosisCoronary Artery Disease Risk Factors Multiple+1 more
Duke University1,500 enrolled23 locationsNCT07232069
Recruiting
Phase 3

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Depressive Disorder, Major
Janssen Research & Development, LLC752 enrolled205 locationsNCT06559306
Recruiting
Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
Johnson & Johnson Enterprise Innovation Inc.45 enrolled19 locationsNCT07219212
Recruiting
Phase 2

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco96 enrolled8 locationsNCT07110246
Recruiting

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC150 enrolled16 locationsNCT07309445
Recruiting
Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled257 locationsNCT06852222
Recruiting
Phase 2

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Major Depressive Disorder
Syndeio Biosciences, Inc164 enrolled34 locationsNCT06547489
Recruiting
Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled193 locationsNCT04892173
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Depressive Disorder, Major
Janssen Research & Development, LLC258 enrolled35 locationsNCT07227454
Recruiting
Phase 3

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder
Intra-Cellular Therapies, Inc.470 enrolled69 locationsNCT05850689
Recruiting
Phase 2Phase 3

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma
Global Coalition for Adaptive Research2,250 enrolled63 locationsNCT03970447
Recruiting
Phase 3

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Gout
Crystalys Therapeutics500 enrolled100 locationsNCT07089875
Recruiting

RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)

Cardiac Arrythmias
Boston Scientific Corporation100 enrolled8 locationsNCT03053141
Recruiting
Phase 1

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease
Disc Medicine, Inc24 enrolled8 locationsNCT07187973
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

Systemic Sclerosis
Boehringer Ingelheim448 enrolledNCT07497087
Recruiting
Phase 1Phase 2

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd542 enrolled82 locationsNCT04657068
Recruiting

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons

Ovarian CancerEndometrial CancerEndometrial Cancer Precursors+1 more
University of Alabama at Birmingham1,700 enrolled1 locationNCT03538665
Recruiting
Phase 2

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

Neurofibromatosis Type 1
Healx Limited25 enrolled14 locationsNCT06541847
Recruiting
Phase 3

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Heart FailureHeart Failure With Reduced Ejection Fraction
Cytokinetics1,800 enrolled199 locationsNCT06736574
Recruiting
Phase 2

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Glomerulonephritis, IGAImmunoglobulin A Nephropathy
Novartis Pharmaceuticals20 enrolled19 locationsNCT06797518